oddge

• Andreassen, Arne K.; Bjørnstad, Johannes Lagethon; Gude, Einar; Nilsen-Hoel, Tom; Broch, Kaspar & Ravnestad, Håvard [Vis alle 8 forfattere av denne artikkelen] (2025). Hjertetransplantasjon i Norge 1983–2023. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 145(12). doi: 10.4045/tidsskr.24.0552. Fulltekst i vitenarkiv Vis sammendrag

  Bakgrunn I november 2023 var det 40 år siden hjertetransplantasjon ble introdusert som et behandlingstilbud ved alvorlig hjertesvikt i Norge. Internasjonale registerdata viser en median overlevelse i overkant av 11 år etter transplantasjon, og de fleste sentrene utfører 10–19 transplantasjoner årlig. Hensikten med denne studien var å gi en oversikt over resultater etter hjertetransplantasjon i Norge. Materiale og metode Studien er en retrospektiv observasjonsstudie av hjertetransplanterte pasienter ved Oslo universitetssykehus, Rikshospitalet i perioden 6.11.1983–31.12.2023, med fokus på pasient- og donorkarakteristika, overlevelse og komplikasjoner. Resultater I tidsrommet 6.11.1983–31.12.2005 ble det i median utført 24 (interkvartilbredde 21–27) hjertetransplantasjoner årlig, mot 32 (29–35) i perioden 1.1.2006–31.12.2023. Blant 1 078 førstegangstransplanterte var median overlevelse 13,4 år (95 % konfidensintervall (KI) 12,7 til 14,4). Median overlevelse var 11,0 år (95 % KI 9,3 til 12,9) for pasienter transplantert 6.11.1983–31.12.1993, 13,1 år (95 % KI 11,7 til 15,4) for pasienter transplantert 1.1.1994–31.12.2003 og 14,8 år (95 % KI 13,5 til 16,8) for pasienter transplantert 1.1.2004 - 31.12.2013. Dette var til tross for stadig økende donoralder og flere transplanterte som kom direkte fra intensivavdeling (ikke elektivt) eller som hadde mekanisk støtte. Overlevelsen var best for pasienter uten iskemisk årsak til hjertesvikt. Ulike former for kreft, sammen med kronisk/progressiv transplantatsvikt (hjerteinfarkt, plutselig død med kjent utvikling av graftsklerose/koronarsykdom/fibrose i graftet), utgjorde de vanligste dødsårsakene. Fortolkning Det har vært en jevn bedring av overlevelsen etter hjertetransplantasjon i Norge. Vårt senter er blant de med høyest aktivitet i verden, og Rikshospitalets resultater er på høyde med de fremste internasjonalt.

• Bjørnstad, Johannes Lagethon; Helgeland, Erik; Geiran, Odd & Fiane, Arnt Eltvedt (2020). Er EXCEL studien relevant for norske forhold? Hjerteforum. ISSN 0802-1465. 33(3), s. 22–28. Fulltekst i vitenarkiv
• Vanem, Thy Thy; Rand-Hendriksen, Svend; Brunborg, Cathrine; Geiran, Odd & Røe, Cecilie (2020). Health-related quality of life in Marfan syndrome: a 10-year follow-up. Health and Quality of Life Outcomes. 18:376, s. 1–8. doi: 10.1186/s12955-020-01633-4. Fulltekst i vitenarkiv Vis sammendrag

  Background Marfan syndrome, a rare hereditary connective tissue disorder caused by mutations in fibrillin-1, can affect many organ systems, especially the cardiovascular system. Previous research has paid less attention to health-related quality of life and prospective studies on this topic are needed. The aim of this study was to assess changes in health-related quality of life after 10 years in a Norwegian Marfan syndrome cohort. Methods Forty-seven Marfan syndrome patients ≥ 18 years were investigated for all organ manifestations in the 1996 Ghent nosology and completed the self-reported questionnaire, Short-Form-36 Health Survey, at baseline in 2003–2004 and at follow-up in 2014–2015. Paired sample t tests were performed to compare means and multiple regression analyses were performed with age, sex, new cardiovascular and new non-cardiovascular pathology as predictors. Results At 10-year follow-up: a significant decline was found in the physical domain. The mental domain was unchanged. Older age predicted a larger decline in physical health-related quality of life. None of the chosen Marfan-related variables predicted changes in any of the subscales of the Short-Form 36 Health Survey or in the physical or the mental domain. Conclusion Knowledge of decline in the physical domain, not related to organ affections, may be important in the follow-up of Marfan syndrome patients.

• Vanem, Thy Thy; Böker, Tordis; Sandvik, Gunhild Falleth; Kirkhus, Eva Astrid; Smith, Hans-Jørgen & Andersen, Kai [Vis alle 13 forfattere av denne artikkelen] (2019). Marfan syndrome: Evolving organ manifestations-A 10-year follow-up study. American Journal of Medical Genetics. Part A. ISSN 1552-4825. 182(2), s. 397–408. doi: 10.1002/ajmg.a.61441. Fulltekst i vitenarkiv Vis sammendrag

  The age‐dependent penetrance of organ manifestations in Marfan syndrome (MFS) is not known. The aims of this follow‐up study were to explore how clinical features change over a 10‐year period in the same Norwegian MFS cohort. In 2003–2004, we investigated 105 adults for all manifestations in the 1996 Ghent nosology. Ten years later, we performed follow‐up investigations of the survivors (n = 48) who consented. Forty‐six fulfilled the revised Ghent criteria. Median age: females 51 years, range 32–80 years; males 45 years, range 30–67 years. New aortic root dilatation was detected in patients up to 70 years. Ascending aortic pathology was diagnosed in 93 versus 72% at baseline. Sixty‐five percent had undergone aortic surgery compared to 39% at baseline. Pulmonary trunk mean diameter had increased significantly compared to baseline. From inclusion to follow‐up, two patients (three eyes) developed ectopia lentis, four developed dural ectasia, four developed scoliosis, three developed incisional or recurrent herniae, and 14 developed hindfoot deformity. No changes were found regarding protrusio acetabuli, spontaneous pneumothorax, or striae atrophicae. The study confirms that knowledge of incidence and progression of organ manifestations throughout life is important for diagnosis, treatment, and follow‐up of patients with verified or suspected MFS.

• Lorén, Christina E.; Dahl, Christen Peder; Do, Lan; Almaas, Vibeke; Geiran, Odd & Mörner, Stellan [Vis alle 7 forfattere av denne artikkelen] (2019). Low Molecular Mass Myocardial Hyaluronan in Human Hypertrophic Cardiomyopathy. Cells. 8(2), s. 1–14. doi: 10.3390/cells8020097. Fulltekst i vitenarkiv Vis sammendrag

  During the development of hypertrophic cardiomyopathy, the heart returns to fetal energy metabolism where cells utilize more glucose instead of fatty acids as a source of energy. Metabolism of glucose can increase synthesis of the extracellular glycosaminoglycan hyaluronan, which has been shown to be involved in the development of cardiac hypertrophy and fibrosis. The aim of this study was to investigate hyaluronan metabolism in cardiac tissue from patients with hypertrophic cardiomyopathy in relation to cardiac growth. NMR and qRT-PCR analysis of human cardiac tissue from hypertrophic cardiomyopathy patients and healthy control hearts showed dysregulated glucose and hyaluronan metabolism in the patients. Gas phase electrophoresis revealed a higher amount of low molecular mass hyaluronan and larger cardiomyocytes in cardiac tissue from patients with hypertrophic cardiomyopathy. Histochemistry showed high concentrations of hyaluronan around individual cardiomyocytes in hearts from hypertrophic cardiomyopathy patients. Experimentally, we could also observe accumulation of low molecular mass hyaluronan in cardiac hypertrophy in a rat model. In conclusion, the development of hypertrophic cardiomyopathy with increased glucose metabolism affected both hyaluronan molecular mass and amount. The process of regulating cardiomyocyte size seems to involve fragmentation of hyaluronan.

• Bendz, Bjørn; Gude, Einar; Ragnarsson, Asgrimur; Endresen, Knut; Aaberge, Lars & Geiran, Odd [Vis alle 7 forfattere av denne artikkelen] (2019). Intra-aortic balloon pump in acute chest pain and cardiogenic shock - a long-term follow-up. Scandinavian Cardiovascular Journal. ISSN 1401-7431. 53(6), s. 337–341. doi: 10.1080/14017431.2019.1657938. Fulltekst i vitenarkiv
• Auråen, Henrik; Durheim, Michael; Dellgren, Gøran; Hämmäinen, Pekka; Larsson, H & Geiran, Odd [Vis alle 11 forfattere av denne artikkelen] (2019). Effect of Donor Age on Outcome of Lung Transplantation Stratified by Recipient Diagnosis: A Nordic Multicenter Study. Transplantation. ISSN 0041-1337. 103(4), s. 807–814. doi: 10.1097/TP.0000000000002402. Fulltekst i vitenarkiv Vis sammendrag

  Background: Organs from older donors are increasingly used in lung transplantation, and studies have demonstrated that this could be safe in selected recipients. However, which recipient groups that have the largest benefit of older organs are unclear. This multicenter study reviews all bilateral lung transplantations (BLTx) from donors 55 years or older stratified by recipient diagnosis and compares outcomes with transplantations from younger donors. Methods: All BLTx recipients (excluding retransplantation) at 5 Scandiatransplant centers between 2000 and 2013 were included (n = 913). Recipients were stratified to diagnosis groups including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and “other.” Intensive care unit (ICU) length of stay (LOS) and survival were assessed. Results: Overall, there was no difference in survival among patients transplanted from donors 55 years or older compared with younger donors. However, in CF recipients, donor age 55 years or older was associated with inferior survival (P = 0.014), and this remained significant in a multivariate model (hazard ratio, 5.0; 95% confidence interval, 1.8–14.1; P = 0.002). There was no significant effect of donor age on survival in recipients with COPD, ILD, or in the “other” group in multivariate models. Utilization of older donors was associated with increased ICU LOS for recipients with CF and ILD, but not in the COPD or “other” group. Conclusions: The BLTx recipients with CF had inferior survival and longer ICU LOS when receiving organs from donors 55 years or older. Recipients with COPD, ILD, or in the “other” group did not have inferior survival in multivariate models.

Se alle arbeider i NVA

• Kvitting, John-Peder; Koul, Bansi & Geiran, Odd (2022). Bjarne K. H. Semb: The contriver of the first implantation of a total artificial heart in Europe. Artificial Organs. ISSN 0160-564X. 46(7), s. 1221–1226. doi: 10.1111/aor.14252. Fulltekst i vitenarkiv
• Bjørnstad, Johannes Lagethon; Helgeland, Erik; Geiran, Odd & Fiane, Arnt Eltvedt (2021). Hjertekirurgi og hjerneskade. Hjerteforum. ISSN 0802-1465. 34(2), s. 104–105. Fulltekst i vitenarkiv
• Bjørnstad, Johannes Lagethon; Fiane, Arnt Eltvedt; Svennevig, Jan Ludvig & Geiran, Odd (2019). Norsk hjertekirurgiregister, et forskriftsregulert nasjonalt medisinsk kvalitetsregister. Hjerteforum. ISSN 0802-1465. 32(1), s. 42–54. Fulltekst i vitenarkiv

Se alle arbeider i NVA